Q&A with hVIVO CEO, Mo Khan
Episode 2022, Jan 21, 11:44 AM
Share
Subscribe
Watch on YouTube
hVIVO has secured a £2.7 million contract for its hLAB division to serve as the sole virology lab for a global Phase 2 influenza drug study involving 5,000 participants. This milestone marks hVIVO's largest standalone lab services contract, leveraging its expanded Canary Wharf facility.
hVIVO has secured a £2.7 million contract for its hLAB division to serve as the sole virology lab for a global Phase 2 influenza drug study involving 5,000 participants. This milestone marks hVIVO's largest standalone lab services contract, leveraging its expanded Canary Wharf facility.